Format

Send to

Choose Destination
Nature. 2011 Dec 7;480(7376):E4-5; discussion E6. doi: 10.1038/nature10615.

GSK-3α/β kinases and amyloid production in vivo.

Author information

1
Experimental Genetics Group, KU Leuven, Leuven, Belgium.

Abstract

Arising from C. J. Phiel, C. A. Wilson, V. M.-Y. Lee & P. S. Klein 423, 435-439 (2003)A major unresolved issue in Alzheimer's disease is identifying the mechanisms that regulate proteolytic processing of amyloid precursor protein (APP)-glycogen synthase kinase-3 (GSK-3) isozymes are thought to be important in this regulation. Phiel et al. proposed that GSK-3α, but not GSK-3β, controls production of amyloid. We analysed the proteolytic processing of mouse and human APP in mouse brain in vivo in five different genetic and viral models. Our data do not yield evidence for either GSK-3α-mediated or GSK-3β-mediated control of APP processing in brain in vivo.

PMID:
22158250
DOI:
10.1038/nature10615
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center